Description

• General description: Tapentadol represents the first new drug of the centrally-acting analgesic class approved in the US in more than 25 years. This Snap-N-Spike® Reference Solution is suitable for many LC/MS or GC/MS applications, including forensic analysis, pharmaceutical analysis, pain prescription monitoring, and urine drug testing.
• Application: Extended-Release Formulation for Chronic Pain: Extended-release formulations of Tapentadol hydrochloride are developed to provide sustained pain relief for chronic conditions. This formulation reduces the frequency of dosing and enhances patient compliance, offering consistent pain management (Faria et al., 2017).Pharmaceutical Quality Control and Research: High-purity Tapentadol hydrochloride solutions are essential in pharmaceutical research and quality control. These solutions are used for the calibration of analytical instruments and ensuring the consistency and safety of pharmaceutical products (Fejos et al., 2014).Transdermal Delivery Systems: Innovative research has developed PEGylated ultra-deformable transferosomes for the transdermal delivery of Tapentadol, improving its bioavailability and analgesic activity. This method offers a non-invasive alternative for pain management (Deng et al., 2022).Innovative Pain Management Solutions: Research on new delivery methods, such as intranasal administration using chitosan nanoparticles, aims to enhance the therapeutic potential and patient compliance of Tapentadol hydrochloride solution for pain management (Javia & Thakkar, 2017).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany